Calliditas Therapeutics
@Calliditas1
Followers
3,221
Following
259
Media
435
Statuses
526
Pioneering treatments for rare diseases. We harness scientific & commercial expertise to improve the lives of patients.
Joined April 2020
Don't wanna be here?
Send us removal request.
Explore trending content on Musk Viewer
Colorado
• 122080 Tweets
Notre Dame
• 108861 Tweets
Garcia
• 59851 Tweets
Kentucky
• 57243 Tweets
#precure
• 52679 Tweets
#仮面ライダーガヴ
• 46175 Tweets
The Weeknd
• 39975 Tweets
プリキュア
• 38565 Tweets
Anita
• 35227 Tweets
Northern Illinois
• 34752 Tweets
Iowa
• 34120 Tweets
#AEWAllOut
• 31594 Tweets
Nebraska
• 29323 Tweets
Abel
• 24136 Tweets
Carti
• 24078 Tweets
Auburn
• 23005 Tweets
#ブンブンジャー
• 21156 Tweets
#UFCVegas97
• 16195 Tweets
Talleres
• 11455 Tweets
ひろプリ
• 10529 Tweets
Calliditas is thrilled to announce that our lead product has been approved by the FDA!
Join our management team for a call at 8am ET (2pm CET) to discuss this exciting news; dial-in info and more details on the approval can be found in our press release:
10
10
119
We’re thrilled to close 2023 with the full FDA approval of TARPEYO. This milestone marks a significant leap forward in the fight against a complex
#RareDisease
, offering renewed hope and possibilities for the patient community:
2
11
77
Calliditas is thrilled to announce that the FDA has accepted the submission and granted Priority Review for the NDA for Nefecon, setting a PDUFA goal date of September 15, 2021.
To read more about this exciting news, check out our press release:
2
5
33
Calliditas today announced positive topline results from Part A of the global Phase 3 clinical trial NefIgArd, which investigated the effect of Nefecon versus placebo in patients with IgA nephropathy. Check out our press release to learn more:
0
6
30
Special thanks to the patients, researchers, clinical staff and Calliditas team for their commitment and hard work leading up to this milestone – the FDA approval of TARPEYO™ (budesonide) delayed release capsules!
#TARPEYO
Learn more here:
3
6
30
We’re thrilled to announce that we won Company of the Year Award at the
@EuroMed_Awards
! Our CEO, Renee Aguiar-Lucander accepted this award, showcasing the best of EU
#mediscience
companies to celebrate achievement & recognize success. Learn more:
1
3
28
In
#IgANephropathy
, increased mucosal galactose-deficient IgA1 in the systemic circulation can trigger autoantibody formation in some individuals. Immune complexes with the autoantibodies become trapped in the kidneys, which can cause progressive damage:
1
3
23
Calliditas is excited to announce our partnership with
@STADA
to commercialize Nefecon in the European Economic Area member states, Switzerland and the UK.
For more details about this partnership, check out our press release:
1
2
26
The doctor’s visit may end, but the support continues. We are proud to offer TARPEYO Touchpoints™ which provides services, assistance, and resources to help access TARPEYO™ (budesonide) delayed release capsules as easily as possible. Learn more here:
0
3
26
#WereHiring
! Our team has exciting career opportunities available in New York, New Jersey and Stockholm! Click here to learn more:
0
1
18
We’re thrilled to announce that
@Kidney_Int
has published the successful results from NefIgArd Part A, our pivotal Phase 3, randomized, double-blind, placebo-controlled, multicenter study. Learn more about the significance of this peer-reviewed article:
3
4
21
We’re thrilled to announce the European Commission has granted marketing authorization for our oral, targeted-release treatment for patients with primary
#IgANephropathy
. Read our press release for details:
0
2
20
Calliditas today announced that the company submitted a Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) for Nefecon. For more info, check out our press release:
0
1
22
Today, our CEO, Renée Aguiar-Lucander, will be presenting at the
@SEBGroup
Nordic Healthcare Seminar.
1
2
21
We are thrilled to share that
@TheLancet
has published the full results from NefIgArd Phase 3 trial in
#IgANephropathy
(
#IgAN
). Learn more here:
0
3
19
Calliditas employee appreciation post! Thank you for your hard work and dedication – it does not go unnoticed and is the heart of our success. Thank you, today and every day!
0
3
18
We’re pleased to announce that the
@MHRAgovuk
Medicines and Healthcare products Regulatory Agency (
#MHRA
), of the United Kingdom has granted Conditional Marketing Authorization (
#CMA
) for our treatment in IgA Nephropathy (
#IgAN
). Learn more:
0
2
17
We're proud to sponsor
@KidneyPatients
' webinar on Jan. 31, 3:00-4:00 pm ET, titled "A Treatment Specifically Designed for IgA Nephropathy, an AAKP HealthLine Innovator Webinar." Accessible to anyone interested in learning about
#IgAN
. Register here:
0
5
16
We are excited to share that
@EuroMed_Awards
has shortlisted Calliditas for the following awards: “Company of the Year”, “Best Communication” and “Breakthrough of the Year”. Learn more about the 20th annual European
#MediscienceAwards
here:
0
4
16
We are honoured to have been nominated for the Mediscience Awards in the 'Best Communication' and 'Breakthrough of the Year' categories, as well as in the 'Chief Executive of the Year' category for our CEO Renée Aguiar-Lucander.
Congratulations to the other nominees!
It gives us great pleasure to reveal the shortlist for this year's European Mediscience Awards 2021!
#congratulations
#shortlist2021
#MediscienceAwards
#success
#achievement
#healthcare
#biotech
#lifesciences
1
10
39
0
1
17
We’re thrilled to announce the primary endpoint was successfully met with positive topline results of our Phase 3 clinical trial investigating the effect of our treatment specifically designed for
#IgANephropathy
(
#IgAN
). Learn more:
0
1
16
We are delighted to be shortlisted for the Clinical Advance of the Year and the Biotech Company of the Year Award at the 2021 Scrip Awards.
Congratulations to the other finalists!
The 2021 Scrip Awards shortlist is here!
Well done to this year’s finalists and thank you to everyone that entered.
Could you be one step closer to taking home a trophy on the night?
Find out who made the shortlist here:
#ScripAwards
0
0
1
0
1
13
Calliditas' lead product candidate Nefecon has been granted accelerated assessment procedure by the EMA. For more info, check out our press release!
2
2
15
#ICYMI
Calliditas was proud to be a part of SPARK symposium hosted by
@IGANFoundation
for
#IgANwarriors
&
#IgAN
experts to come together to address current & future treatments options. We’re delighted to have participated in & sponsored an impactful event like this!
#SPARK2022
0
4
14
New faces at Calliditas! You may be visited by a member of our newly formed sales team soon! HCPs -
#RequestARep
by visiting our website here:
0
2
13
#ICYMI
, Calliditas is sponsoring “Looking Upstream in IgAN: The Role of The Gut and Its Implications” Medical Symposium on February 25, 2022. Register here to listen to our speakers
@cheekaycheung
and Dr. Richard Lafayette:
@ISNkidneycare
@ISNWCN
#ISNWCN
0
5
15
The
@EuroMed_Awards
has shortlisted Calliditas for the Breakthrough of the Year Award! We are proud to standout in this category. Learn more about the 21st annual European
#MediscienceAwards
here:
0
4
15
Why target the gut to treat
#IgAnephropathy
? Find out in this article: by
@IgAN_Jbarratt
, a leading expert in
#IgAN
, and at .
1
3
15
Have you visited our new TARPEYO™ website for healthcare providers? Click here to learn everything you need to know about FDA-approved TARPEYO™ (budesonide) delayed release capsules:
0
3
14
We just announced receipt of a Notice of Allowance from the USPTO for TARPEYO® (budesonide) delayed release capsules. This will be our 2nd U.S. patent & will significantly strengthen TARPEYO's IP protection, further improving its unique value proposition.
0
1
14
Check out
@IGANFoundation
’s new guide, "IgA Nephropathy – What You Need to Know" to learn how you can stay on top of IgA nephropathy and help to possibly slow its progression:
0
4
14
We'd like to thank everyone who has supported and joined our mission in advancing treatments for rare diseases, making this year a success. Wishing you all a warm, happy, and healthy holiday season!
0
0
15
Our CEO, Renée Aguiar-Lucander, will be presenting at
@HCWCO
Bioconnect Conference. Click here to register:
0
2
14
#IgANephropathy
is a chronic
#AutoimmuneDisease
with no
#FDA
-approved disease-specific treatments. U.S. HCPs - Stay connected with Calliditas beyond
#IgANephropathyAwarenessMonth
and be the first to receive our latest
#IgAN
news and updates here:
0
3
12
Have you seen the
#BehindtheMystery
segment that aired on
@BalancingActTV
that focuses on
#IgANephropathy
? The video features patients with
#IgAN
and
#IgAN
expert
@IgAN_Jbarratt
. You can watch the full video here: .
0
3
12
We're thrilled to attend IIgANN Tokyo, Sept. 28-30, with five poster and three oral presentations. Members of our leadership team will be there to meet with IgA nephropathy (
#IgAN
) experts and share our commitment to improve patient outcomes. See you there!
0
3
12
Today is
#WorldKidneyDay
& Calliditas is a proud sponsor! Join us in honoring National Kidney Month by raising awareness of
#KidneyDiseases
. This year’s theme is to bridge the knowledge gap to better kidney care. Learn more & get involved:
@worldkidneyday
0
2
13
We’re thrilled to announce our commercial partner,
@STADA
has launched the first and only medicine authorized in the EU for treating primary
#IgANephropathy
. Read our press release for details:
0
2
12
We are thrilled to share that
#FDAapproved
TARPEYO™ (budesonide) delayed release capsules will have a booth
#907
at the
@nkf
Spring Clinical Meetings in Boston, MA from April 6-10, 2022! Learn more and register here:
0
1
13
Our CEO, Renée Aguiar-Lucander, has won this year’s “Women Led Business Leader of the Year” award at the
@LSXLeaders
European Lifestars Awards! A big congratulations to all the winners & finalists across all categories. It's wonderful to see such talent and innovation recognized.
0
1
13
We're proud to sponsor
@KidneyPatients
' webinar, where
@IgAN_JBarratt
will share insights on
#IgANephropathy
& a treatment specifically designed for this
#RareDisease
. Available to anyone interested in learning more about
#IgAN
, register now:
Register for our upcoming webinar to learn about a treatment specifically designed for IgA Nephropathy! Also learn about IgA Nephropathy, discover a treatment that was specifically designed for this disease, and review clinical trial results.
@Calliditas1
0
3
10
0
2
11
As the new year kicks off, we're eager to take steps toward our 2023 milestones. Our talented team is driven to rapidly and efficiently establish a new standard of care in
#OrphanIndications
, such as
#PBC
and
#IgAN
.
0
0
11
Established in 2004, we’ve been at the forefront of scientific innovation, devoted to improving the lives of those affected by
#RareDiseases
. With a strong foundation & nearly two decades of experience, we’re poised for continued success. Read our history:
0
0
12
Calliditas has secured a $75 million term loan facility. For more details, check out our press release:
0
0
12
Congratulations to Calliditas CEO Renee Aguiar-Lucander who was named CEO of the year by the
@EuroMed_Awards
for her continued leadership and commitment to the development of therapies for patients affected by
#orphandiseases
with unmet medical needs!
#MediScienceAwards
0
0
12
We're proud to have been a part of another successful SPARK event hosted by
@IGANFoundation
. It was great to see new & familiar faces at
#SPARK2023
. We're inspired by the patients, loved ones, caregivers, & healthcare professionals who shared their journeys to a brighter future.
0
2
12
Calliditas will head to Bangkok for
@ISNWCN
's World Congress of Nephrology (
#ISNWCN
)! We've gathered
@IgAN_JBarratt
, Professor Yusuke Suzuki, and Dr. See Cheng Yeo for a panel on "Evolving Landscape in IgA Nephropathy Patient Management." See you there:
0
3
12
Our partner, Everest Medicines, secured approval of the first-and-only IgA nephropathy (IgAN) therapy in China, where up to 5 million individuals live with
#IgAN
. This is a critical step to address the urgent unmet need of the patient community. Read more:
0
1
12
Today, we celebrate the life of Dr. Jean Berger, a renal
#pathologist
known for first describing
#IgANephropathy
and coining the term “Berger’s Disease.” Learn more about Dr. Berger and his groundbreaking work in
#KidneyDisease
here:
0
3
11
#DYK
your
#kidneys
are powerful organs that are essential to your health? Support
#WorldKidneyDay
with us and
@worldkidneyday
– take a picture and
#ShowYourKidneys
! Learn more:
1
3
12
On April 3rd, our CEO, Renée Aguiar-Lucander, will participate in a
#FiresideChat
at the Guggenheim Healthcare Talks:
#Genomic
Medicines and
#RareDisease
Days. Stay tuned to learn more about our participation in other upcoming investor conferences:
0
1
11
Thanks for the shoutout
@IGANFoundation
! We are so excited to be involved with such an important, informative, and memorable weekend for
#IgANCommunity
.
We are so excited for SPARK. Special thanks to one of our Champion Sponsors Calliditas. See you soon.
#thefuturelooksbright
#iganspark
#spark2023
0
1
5
0
1
11
July is
#IgANephropathyAwarenessMonth
.
#IgANephropathy
is a chronic
#AutoimmuneDisease
with no
#FDA
-approved disease-specific treatments. Learn more
#IgAN
and about the hidden culprit that could impact advancements in new treatments:
0
2
11
In 2021, Calliditas became the first company to receive accelerated approval in
#IgANephropathy
. We look forward to initiating additional clinical trials and sharing clinical results from these studies as they progress. View the full year report here:
0
1
11
Calliditas is proud to participate in the 11th Annual LifeSci Partners Corporate Access Event, January 5-7, 2022. Click here to register:
0
2
10
Here at the Calliditas office, we take a break every Friday called Fika, an important tradition tied to our Swedish roots. This time is used to recharge & connect with colleagues over coffee & snacks. Find out a little bit more about our company culture in future
#FikaFridays
!
1
2
11
We’re honored that our CEO, Renee Aguiar-Lucander, was considered among other talented industry leaders for the
@PharmaScrip
#ScripAwards
: Executive of the Year. Join us in recognizing all nominees and winners of the 2022 Scrip Awards:
0
1
11
Our CEO, Renee Lucander, has been shortlisted for the 2022
@PharmaScrip
#ScripAwards
: Executive of the Year, for leadership excellence in
#pharmaceutical
&
#biotech
companies. We’re honored to be selected among such talented industry leaders. Learn more:
0
2
11
Renowned
#nephrologist
Dr. Dana Rizk is back to discuss the potential use of biomarkers & their role in clinical practice on our new website
#IgANexus
, developed in collaboration with
#nephrology
&
#immunology
experts. Watch the full-length video here:
4
0
10
Meet the
#CalliditasCommunity
! We’d like to highlight Katayoun Welin-Berger, Vice President, Operations. Katayoun is a leader with more than 28 years of commercial experience in the pharmaceutical and biologics industry. Learn more about our team here:
0
2
11
Calliditas will present at the Jefferies Virtual Healthcare Conference on Tuesday, June 1, 2021 at 2:30pm CET/ 8:30am ET.
To register, follow the link below:
0
0
10
Join us at
@ERAkidney
’s 60th ERA Congress on June 16 as we present our full Phase 3 trial results evaluating our treatment in
#IgANephropathy
(
#IgAN
), and more. Read details on our
#ERA23
presentations and e-posters here:
0
1
11
Today marks the initiation of our Phase 2 clinical study to evaluate the safety and tolerability of setanaxib in patients with
#AlportSyndrome
. Our innovative potential therapy is being studied to delay the progression to
#KidneyFailure
. Read more:
0
4
11
We are a proud sponsor of this year's
@KidneyPatients
' virtual
#AAKPFunWalk22
from Dec. 5-9. This is a wonderful opportunity for communities from around the world to participate on their own schedule and raise awareness for
#KidneyDisease
! Register here:
0
4
10
As research continues, a clearer picture of the possible
#pathophysiology
of
#IgANephropathy
is emerging in the gut-kidney axis. Calliditas is researching new ways to target the gut in an effort to change the course of this
#KidneyDisease
. Learn more:
0
1
8
March is
#NationalKidneyMonth
! Calliditas is raising awareness all month long. Be sure to mark your calendars with these key dates:
0
4
10
#WeAreHiring
! Calliditas has incredible career opportunities available in New York, Sweden, and Switzerland, with remote positions available as well! Click here to learn more:
0
0
10
Happy New Year! Calliditas is looking forward to another year of commitment to patients affected by
#OrphanDiseases
with unmet medical needs. Learn more:
0
1
10
Green looks good on our Stockholm team! It represents
#kidney
awareness and hope for those affected by
#KidneyDisease
. We’re proud to see them sporting this color in support of
#NationalKidneyMonth
on our mission to develop novel therapies for those impacted by
#RareDiseases
.
0
1
10
Today we're celebrating the one-year accelerated approval by the FDA of our product TARPEYO® (budesonide) delayed-release capsules. We’re grateful for the patients, researchers, & our team who made this possible & we are looking forward to years ahead.
1
0
10
We are pleased to share our 2022 milestones in our Annual Report, including becoming the first company to commercialize a disease-specific treatment in IgA Nephropathy (
#IgAN
). Swipe below for highlights and read the release to learn more:
0
0
10
We are participating in ASN Kidney Week 2021 from Thursday, November 4, 2021 - Sunday, November 7, 2021. For more information read our press release here
#KidneyWk
:
0
1
8
Our CEO, Renée Aguiar-Lucander, will participate in a panel alongside peer industry leaders at
@ftlive
’s Global Pharma and Biotech Summit, where she will share her insights on the power of strategic partnerships in
#LifeSciences
. For details:
#FTPharma
0
0
10
Today, we're celebrating the two-year anniversary of the accelerated approval of TARPEYO in the U.S. We would like to acknowledge the patients, researchers, and HCP community whose dedication continues to lead to exciting milestones!
0
0
10
Our CFO, Fredrik Johansson, is presenting a corporate overview at
@Pareto_Sverige
Securities’ 13th Annual Healthcare Conference. We’re looking forward to representing Calliditas amongst other Swedish & international
#pharmaceutical
companies. Learn more:
0
1
10
In the latest episode of
@PharmaCommerce
our President, North America, Andy Udell, discusses the complexities of bringing new
#RareDisease
products to market and more. Listen here to learn about his insights on achieving success in the rare disease space:
0
2
10
Calliditas is honored to have sponsored such an exciting new resource tool for the community. Check it out!
We are proud to announce the release of our guide: IgA Nephropathy–What You Need to Know. We hope it will provide valuable information and hope to those newly diagnosed. Access the full guide today and play an active role in your care.❤️💙
#iganephropathy
0
1
3
0
1
8
We are pleased to announce that the ClinicoEconomics & Outcomes Research (CEOR) peer-reviewed journal has published the cost-effectiveness analysis of our FDA-approved treatment specifically designed for IgA Nephropathy (
#IgAN
). Learn more here:
0
2
9
Why target the gut in
#IgAnephropathy
? Watch Dr. Barratt to learn more about the gut-kidney axis as it relates to
#IgAN
.
0
1
9
We’re joining our friends at
@IGANFoundation
in recognizing the first
#IgANephropathyAwarenessDay
on May 14. Learn how you can get involved here:
#IgANAware
#IgANDay
0
2
8
Today is
#RareDiseaseDay
, a day led by
@rarediseaseday
dedicated to raising awareness worldwide for all those affected. Our team is committed to bringing new treatments to market for
#RareDiseases
. Discover more about our work here:
0
2
8
Join us today for a poster and an oral presentation highlighting data from our work in rare
#KidneyDiseases
at
@ASNKidney
’s
#KidneyWk
. Find us in the Exhibit Hall & Room 103 to learn about our
#eGFR
data for
#IgAN
and data from a study of our NOX inhibitor for
#AlportSyndrome
.
0
1
9
We're excited to share that Calliditas will have two late-breaking presentations at
@ERAkidney
's 60th ERA Congress in Milan from June 15-18. Read more about our
#ERA23
presentations and e-posters here:
0
1
9
Today is International
#PrimaryBiliaryCholangitis
Day!
@PBCers
supports those affected and provides educational resources about PBC. Calliditas is striving to develop a potential treatment for this
#RareDisease
. Learn more here:
1
2
8
October is National Liver Month! Calliditas is at the forefront of innovation to address current unmet needs for Primary Biliary Cholangitis, a progressive
#autoimmune
#RareDisease
of the liver. We're honored to have seasoned experts, HCPs, and researchers join our mission.
0
0
9
We are extremely proud that our CEO, Renée Aguiar-Lucander, was nominated a finalist in this year’s ‘Executive of the Year’ award at the
#ScripAwards
! It’s great to be nominated among fellow biotech companies who contributed innovative science and solutions this year.
0
0
9
Our CEO, Renee Aguilar-Lucander, sat down with the
@DrillDownPod
to discuss the company, our pipeline of
#OrphanIndications
, our FDA-approved treatment for IgA Nephropathy (
#IgAN
), and plans to share additional data in 2023. Tune in at 22:35 to learn more:
0
3
9
Watch the full
#BehindtheMystery
segment about IgA Nephropathy, which aired on
@BalancingActTV
yesterday morning, to learn more about living with
#IgAN
and the challenges patients face due to unmet treatment needs.
0
2
8
Hello, Twitter! We're Calliditas and we are committed to developing global, high-value therapies for patients with
#rarediseases
To find out more, visit .
0
2
9
#IgANephropathy
causes inflammation in the kidney glomeruli, leading to the progressive decline of renal function & the destruction of the kidney’s filtration mechanism. Click here to learn about our product in development:
0
2
9
It was an honor to connect with the rare
#KidneyDisease
community at
@ASNKidney
’s
#KidneyWk
& showcase our pioneering work in IgA nephropathy. Learn about the additional analyses we presented from our Ph3 NefIgArd trial for the treatment of
#IgAN
, & more:
1
1
9